The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with hepatocellular carcinoma: A meta-analysis.
The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with hepatocellular carcinoma: A meta-analysis.
复制标题
DOI：
10.1038/srep46601
复制
发表时间：
2017-04-18
影响因子：
4.6
通讯作者：
Zou SB
中科院分区：
文献类型：
--
作者：
Song W;Tian C;Wang K;Zhang RJ;Zou SB
据报道，淋巴细胞与单核细胞比率（LMR）可以预测多种恶性肿瘤的临床结果。本研究的目的是评估预处理 LMR 在肝细胞癌 (HCC) 中的预后作用。荟萃分析共纳入 7 项研究，涉及 2,738 名患者。汇总结果显示，LMR 升高与总生存期 (OS)（HR：0.31，95% CI：0.20–0.47，p< 0.001）、无病生存期（DFS）/无复发生存期（RFS）（HR：0.57，95% CI：0.49–0.67， p < 0.001)。在具有不同样本量、出版物类型、NOS 评分和 LMR 截止值的所有亚组中，观察到高 LMR 对 OS 的有利预后影响。此外，低LMR与TNM分期和BCLC分期显着相关。因此，我们得出结论，治疗前 LMR 升高可能是 HCC 患者临床结果的有利预后因素。
The lymphocyte-to-monocyte ratio (LMR) has been reported to predict clinical outcomes in multiple malignancies. The aim of this study was to assess the prognostic role of pretreatment LMR in hepatocellular carcinoma (HCC). A total of seven studies comprising 2,738 patients were included in the meta-analysis. Pooled results showed that elevated LMR was significantly associated with increased overall survival (OS) (HR: 0.31, 95% CI: 0.20–0.47, p < 0.001), disease-free survival (DFS)/recurrence-free survival (RFS) (HR: 0.57, 95% CI: 0.49–0.67, p < 0.001). The favorable prognostic impact of high LMR on OS was observed in all subgroup with different sample size, type of publication, NOS score, and the cut-off value of LMR. In addition, low LMR was significantly correlated with TNM stage and BCLC stage. We therefore conclude that elevated pretreatment LMR could be a favorable prognostic factor for clinical outcomes in patients with HCC.